valarox 160 mg + 10 mg tabletki powlekane
krka, d.d., novo mesto - valsartanum + rosuvastatinum - tabletki powlekane - 160 mg + 10 mg
valarox 160 mg + 20 mg tabletki powlekane
krka, d.d., novo mesto - valsartanum + rosuvastatinum - tabletki powlekane - 160 mg + 20 mg
olvastim 10 mg tabletki powlekane
accord healthcare polska sp. z o.o. - atorvastatinum calcicum trihydricum - tabletki powlekane - 10 mg
olvastim 20 mg tabletki powlekane
accord healthcare polska sp. z o.o. - atorvastatinum calcicum trihydricum - tabletki powlekane - 20 mg
olvastim 40 mg tabletki powlekane
accord healthcare polska sp. z o.o. - atorvastatinum calcicum trihydricum - tabletki powlekane - 40 mg
olvastim 80 mg tabletki powlekane
accord healthcare polska sp. z o.o. - atorvastatinum calcicum trihydricum - tabletki powlekane - 80 mg
rosulip plus 5 mg + 10 mg kapsułki twarde
egis pharmaceuticals plc - rosuvastatinum + ezetimibum - kapsułki twarde - 5 mg + 10 mg
rozor 10 mg + 10 mg tabletki powlekane
mylan ire healthcare ltd - rosuvastatinum calicum + ezetimibum - tabletki powlekane - 10 mg + 10 mg
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Środki przeciwnowotworowe - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
rosulip pro 10 mg + 10 mg kapsułki twarde
egis pharmaceuticals plc - rosuvastatinum + ezetimibum - kapsułki twarde - 10 mg + 10 mg